Buprenorphine IV

ApprovedSmall molecule

PPurdue Pharma LP

Buprenorphine IV is one of 162 small molecule programs targeting Low back pain. It is currently in Approved.

Indications

Total Trials

Active Trials

161

Competitors

Pipeline

Status by Indication[3][1]

Indication

Low Back PainActive, not recruiting

Restless Legs SyndromeActive, not recruiting

Chronic PainActive, not recruiting

Back PainActive, not recruiting

OsteoarthritisActive, not recruiting

Low Back PainPhase 3

Active, not recruiting

Restless Legs SyndromeApproved

Active, not recruiting

Chronic PainPhase 3

Active, not recruiting

Back PainPhase 3

Active, not recruiting

OsteoarthritisPhase 3

Active, not recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Buprenorphine IV

PPurdue Pharma LP

Approved

2 2

Epidiolex

Jazz Pharmaceuticals

Preclinical

4 3

Ilaris

Novartis

Preclinical

2 4

Bayer Aspirin

Cataflam

Chirocaine

1 7

Lunesta

Akero Therapeutics

Preclinical

1 8

SGLT2 Inhibitor

Eli Lilly

Preclinical

1 9

Decadron

QQuince Therapeutics S.p.A.

Ozone

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Osteoarthritis2 trials

The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.

Completed·PPurdue Pharma LP·Phase 3·NCT00315848·225 enrolled

Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.

Completed·PPurdue Pharma LP·Phase 3·NCT00314652·260 enrolled

Pediatric Patients1 trial

Pharmacokinetics, Safety, and Efficacy of Intravenous Dosing of Buprenorphine in Pediatric Patients Who Require Opioid Analgesia for Acute Moderate to Severe Pain

Withdrawn·PPurdue Pharma LP·Phase 3·NCT01324544

Restless Legs Syndrome1 trial

Butrans for Treatment of Restless Legs Syndrome

Withdrawn·MMassachusetts General Hospital·Phase 4·NCT02138357

Orthopedic Surgery1 trial

Safety of the Buprenorphine Transdermal Delivery System in Subjects With Mod-to-Sev Pain Following Orthopedic Surgery.

Completed·PPurdue Pharma LP·Phase 2·NCT00315835·100 enrolled

Back pain1 trial

The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Back Pain.

Completed·PPurdue Pharma LP·Phase 3·NCT00315887·250 enrolled

2 more indications

Chronic pain1 trial

Safety and Effectiveness of Buprenorphine Transdermal System in Elderly Subjects With Chronic Pain: Pilot Study.

Completed·PPurdue Pharma LP·Phase 3·NCT00313833·100 enrolled

Low back pain1 trial

The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Low Back Pain.

Completed·PPurdue Pharma LP·Phase 3·NCT00315874·225 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Buprenorphine IV. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Buprenorphine IV compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Buprenorphine IV. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Purdue Pharma LP company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: PPurdue Pharma LP

Buprenorphine IV

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Osteoarthritis2 trials

Pediatric Patients1 trial

Restless Legs Syndrome1 trial

Orthopedic Surgery1 trial

Back pain1 trial

Chronic pain1 trial

Low back pain1 trial

References

Drug Info

Quick Facts

Related News